Caris Life Sciences Raises $830M in Growth Equity Funding Caris Life Sciences, an Irving, Texas-based innovator in molecular science and artificial intelligence (AI) focused on fulfilling the promise of precision medicine, raised $830m in growth equity funding at a post-money valuation of $7.83 billion. The round was led by Sixth Street, with participation from funds and accounts advised by T. Rowe Price Associates, Inc., Silver Lake, Fidelity Management & Research Company LLC, Coatue, Columbia Threadneedle Investments, Canada Pension Plan Investment Board, Millennium Management, Neuberger Berman Funds, Highland Capital Management, Rock Springs Capital, OrbiMed, ClearBridge Investments, Tudor Investment Corporation, Eaton Vance Equity (Morgan Stanley), Pura Vida Investments and First Light Asset Management.